Switzerland biotech funding rose 2.1% to 2.6B francs ($3.32B) in 2025 as private investment surged 38% to offset tight capital markets. Private capital now accounts for nearly half of all sector funding, according to the Swiss Biotech Report 2026. Investors are pivoting toward R&D collaborations and licensing deals to de-risk structures in a challenging post-pandemic environment.

Private Capital Fills the Public Market Gap